Free Trial

Genprex (GNPX) Competitors

$2.20
-0.01 (-0.45%)
(As of 05/24/2024 03:59 PM ET)

GNPX vs. TCRT, KALA, AYTU, TLPH, GLYC, GLTO, NERV, TNXP, FLGC, and ORGS

Should you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Alaunos Therapeutics (TCRT), KALA BIO (KALA), Aytu BioPharma (AYTU), Talphera (TLPH), GlycoMimetics (GLYC), Galecto (GLTO), Minerva Neurosciences (NERV), Tonix Pharmaceuticals (TNXP), Flora Growth (FLGC), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical preparations" industry.

Genprex vs.

Genprex (NASDAQ:GNPX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Genprex currently has a consensus price target of $10.00, indicating a potential upside of 354.55%. Given Genprex's stronger consensus rating and higher probable upside, analysts plainly believe Genprex is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genprex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alaunos Therapeutics
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Alaunos Therapeutics' return on equity of -229.55% beat Genprex's return on equity.

Company Net Margins Return on Equity Return on Assets
GenprexN/A -272.65% -198.07%
Alaunos Therapeutics N/A -229.55%-173.67%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A-$30.86MN/AN/A
Alaunos TherapeuticsN/AN/A-$35.14MN/AN/A

Genprex has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500.

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Genprex. MarketBeat recorded 3 mentions for Alaunos Therapeutics and 2 mentions for Genprex. Genprex's average media sentiment score of 0.94 beat Alaunos Therapeutics' score of 0.93 indicating that Genprex is being referred to more favorably in the media.

Company Overall Sentiment
Genprex Positive
Alaunos Therapeutics Positive

14.1% of Genprex shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 11.5% of Genprex shares are owned by insiders. Comparatively, 5.1% of Alaunos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genprex received 192 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 65.25% of users gave Genprex an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote.

CompanyUnderperformOutperform
GenprexOutperform Votes
199
65.25%
Underperform Votes
106
34.75%
Alaunos TherapeuticsOutperform Votes
7
58.33%
Underperform Votes
5
41.67%

Summary

Genprex beats Alaunos Therapeutics on 8 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNPX vs. The Competition

MetricGenprexPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$4.62M$6.50B$5.00B$8.04B
Dividend YieldN/A2.79%2.83%3.96%
P/E RatioN/A21.91158.7118.37
Price / SalesN/A240.422,542.2474.09
Price / CashN/A19.2232.9728.78
Price / Book0.445.864.964.40
Net Income-$30.86M$120.76M$103.77M$213.17M
7 Day Performance-10.20%-3.09%-1.32%-1.39%
1 Month Performance-0.45%0.98%3.36%3.10%
1 Year Performance-93.82%-4.55%5.37%7.51%

Genprex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
0 of 5 stars
$1.15
+6.5%
N/A-84.7%$18.41MN/A0.001Positive News
KALA
KALA BIO
3.9679 of 5 stars
$6.51
+0.2%
$16.50
+153.4%
-56.7%$18.36M$3.89M-0.4343Positive News
AYTU
Aytu BioPharma
3.2684 of 5 stars
$3.20
+0.6%
$5.00
+56.3%
+90.5%$17.82M$107.40M-1.22150Positive News
TLPH
Talphera
1.6996 of 5 stars
$1.03
-1.0%
$4.50
+336.9%
N/A$17.50M$650,000.00-1.1615
GLYC
GlycoMimetics
3.8397 of 5 stars
$0.27
flat
$10.00
+3,603.7%
-85.4%$17.40M$10,000.00-0.4735
GLTO
Galecto
1.882 of 5 stars
$0.63
+1.6%
$5.33
+746.7%
-71.9%$17.08MN/A-0.5513Positive News
NERV
Minerva Neurosciences
3.8619 of 5 stars
$2.44
-3.2%
$7.00
+186.7%
-59.1%$17.07MN/A-0.559Analyst Forecast
Positive News
TNXP
Tonix Pharmaceuticals
2.3786 of 5 stars
$0.18
flat
$5.50
+3,033.9%
-89.5%$16.77M$7.77M-0.03103Gap Up
FLGC
Flora Growth
3.2782 of 5 stars
$1.30
+8.3%
$6.00
+361.5%
-73.9%$16.67M$76.07M0.0097Positive News
Gap Up
ORGS
Orgenesis
2.1695 of 5 stars
$0.48
-2.0%
N/A-60.7%$16.53M$530,000.000.00146

Related Companies and Tools

This page (NASDAQ:GNPX) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners